Physician profile
Francis M Jampol
NPI 1871551812
$918.82
in general payments reported to CMS, 2019-2025
19 companies · $40.37 in 2025
The $40.37 reported for 2025 was less than what a typical Otolaryngology/Facial Plastic Surgery provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $300 · 2020: $166 · 2021: $115 · 2022: $267 · 2023: $16.89 · 2024: $14.03 · 2025: $40.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $71.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $71.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $273.73 | 2019-2022 | |
| Glaxosmithkline, LLC. | $156.05 | 2019-2023 | Nucala |
| Optinose US, INC. | $138.30 | 2019-2022 | |
| Alk-Abello, INC | $52.33 | 2019-2022 | |
| Davol INC. | $42.48 | 2021 | |
| Stryker Corporation | $40.40 | 2019 | |
| Aerin Medical INC. | $39.81 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.46 | 2025 | |
| Axsome Therapeutics, INC. | $15.91 | 2025 | Auvelity |
| Amgen INC. | $15.00 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.93 | 2022 | |
| Sanofi-Aventis U.S. LLC | $14.48 | 2020 | |
| Novartis Pharmaceuticals Corporation | $14.42 | 2019 | |
| Xeris Pharmaceuticals, INC. | $14.03 | 2024 | Gvoke Hypopen |
| Kaleo, INC. | $13.64 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $12.90 | 2019 | |
| Csl Behring | $12.81 | 2020 | |
| Arbor Pharmaceuticals, INC. | $11.70 | 2019 | |
| Ethicon US, LLC | $11.44 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Francis Jampol listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.